AKT1 and breast neoplasm: Accordingly, both depletion of FOXA1, and the chemical inhibition of IGF1‐R and AKT by MK‐2206, an AKT inhibitor in clinical trials for the treatment of breast tumors [39], in MCF‐7 cells all reduced the expression levels of each protein in the pathway (Figs S4C and S5A–C).